Akers Biosciences (AKER) executive Rivard received 154,360 Stock Option (Right to Buy)

Insider transactions reported

Paul Rivard (executive at Akers Biosciences Inc., AKER) reported that they received 154,360 Stock Option (Right to Buy) on Apr 16, 2021.

Reporting person

Rivard Paul

Options and other derivatives

Holdings before and after

• Stock Option (Right to Buy): 0 to 77,180 direct
• Stock Option (Right to Buy): 0 to 77,180 indirect, See footnote

Footnotes from the filing

1. 1. Received in exchange for a stock option to acquire 200,000 shares of common stock of a private company formerly known as MyMD Pharmaceuticals, Inc. (the Former Entity ) at $1.00 per share in connection with the merger of the Former Entity with and into a wholly owned subsidiary of the Issuer (the Merger ). On the effective date of the Merger, the closing price of the Issuer's common stock was $4.94 per share.
2. 2. These options are fully vested and exercisable.
3. 3. Received in exchange for a stock option to acquire 200,000 shares of common stock of the Former Entity at $1.00 per share in connection with the Merger.
4. 4. These shares are jointly held by the reporting person and Jennifer Rivard as trustees for the Paul Rivard and Jennifer Rivard Revocable Living Trust.

Transaction codes in this filing

Grant or award:

Code A marks a grant or award from the company under an exempt employee or director plan. Usually nothing is paid for it.

FAQ